Kalamazoo, Michigan (PRWEB) November 04, 2016
accuFD, inc. announced today the location of its corporate offices and lab space within the Western Michigan University School of Medicine Incubator in Kalamazoo, Michigan.
“Kalamazoo offers a long history in life sciences product development across the therapeutic, medical device and diagnostic spectrum, with a very strong scientific and entrepreneurial talent pool,” stated Paul Neeb, CEO of accuFD. “We’re in an excellent position to capitalize and rapidly grow our business from our base in Michigan.”
accuFD was launched earlier this year by the technology commercialization firm Vener8 Technologies, Inc., to bring to market innovative blood sample preparation devices based on a portfolio of microfluidics technologies and patents licensed from General Electric (GE). accuFD is initially targeting the emerging liquid biopsy and non invasive pregnancy testing markets, where its devices promise enhanced sample quality and workflow over incumbent patient sample management techniques.
Pat Patnode, President of GE Ventures – Licensing, said, “We’re excited for accuFD to be part of the biomedical ecosystem of southwestern Michigan as it pursues a global commercialization strategy for this high potential technology.”
accuFD looks forward to growing its Kalamazoo presence with additional biology, fluidic systems and biomechanical professionals in the near future.
About GE Ventures
GE Ventures is committed to identifying, scaling, and accelerating ideas that will make the world work better. Focused on the areas of software, advanced manufacturing, energy, and healthcare, GE Ventures helps entrepreneurs and start-ups succeed by providing access to GE’s technical expertise, capital, and opportunities for commercialization through GE’s global network of business, customers, and partners. GE Ventures offers an unparalleled level of resources through its Global Research Center, including: 35,000 engineers; 5,000 research scientists; 8,000 software professionals; as well as 40,000 sales, marketing, and development resources in over 100 countries. For more information, please visit http://www.geventures.com.
About accuFD
accuFD, a Vener8 Technologies company, is commercializing innovative blood sample management technologies to eliminate pre-analytical variability for emerging point-of-care, NGS and PCR based diagnostic applications. With technology licensed from General Electric, the accuFD platform will enable the rapid separation of cells and cell-free components to eliminate the problems of analyte degradation and contamination associated with current patient sample management techniques. To learn more, please visit http://www.accufd.com.
About Vener8 Technologies
Vener8 is a technology holding company that commercializes proven technologies from leading corporate partners. By combining entrepreneurial zeal with disruptive technologies in large markets, Vener8 is building businesses that matter. To learn more, please visit http://www.vener8tech.com.